Peptide Aggregation in Manufacturing
Peptide Aggregation in Manufacturing: Mechanisms, Challenges and Case Studies
Wednesday, June 18, 2025 | 10am EDT (NA) / 3pm BST (UK) / 4pm CEST (EU-Central) 60 min
Peptide therapeutics have become an essential modality in treating chronic and complex diseases, including cancer, diabetes and neurodegenerative disorders. However, peptide manufacturing presents persistent challenges, particularly peptide aggregation, which can significantly reduce product yield, bioactivity and safety.
This webinar will provide an in-depth examination of peptide aggregation during drug substance and drug product development, highlighting root causes, detection tools and effective mitigation strategies grounded in real-world case studies.
The featured speakers will begin with an overview of peptide aggregation mechanisms. They will discuss how intrinsic factors such as amino acid sequence and hydrophobicity, along with extrinsic parameters like pH, temperature, stirring and buffer composition, contribute to aggregate formation. Aggregation often occurs during downstream processes, forming amorphous clumps, fibrils or crystalline structures that compromise therapeutic integrity and can trigger immunogenic responses.
Register to webinar on Xtalks
Speakers:
- El Djouhar Rekaï, PhD, Head of Process & Analytical Development, PolyPeptide Group
- Anaïs Pujol-Collinson, PhD, Downstream Process Scientist, PolyPeptide Group
- Dinesh Parmar, Head of Regulatory Affairs Ambernath, PolyPeptide Group